Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transition From Biomarkers To Surrogate Endpoints Will Be Subcmte. Topic

This article was originally published in The Pink Sheet Daily

Executive Summary

The subcommittee will focus on the planning and process of the transition from biomarkers to surrogate endpoints for drugs under FDA’s “Critical Path” initiative. Updating approved drug labeling to include pharmacogenetic information will also be discussed at the Nov. 3-4 meeting.

You may also be interested in...



FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting

The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.

FDA Science Board Will Look At “Future Plans” For “Critical Path” At Nov. 5 Meeting

The meeting is one of several by the agency to discuss the drug development initiative. The final report of FDA’s good manufacturing practices initiative will also be reviewed.

FDA Initiative Encourages Use Of Imaging Technologies To Identify Biomarkers

An FDA working group will develop guidance on the use of imaging to speed drug development. Locating the biomarkers will require coordination between manufacturers and the imaging industry.

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel